Findings

What do systematic reviews say?

Ignored "BT": search terms need at least 3 characters.

707 questions · 750 findings · 36 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 56 · 7.5%GRADE not reported 200 · 26.7%Very low 142 · 18.9%Low 186 · 24.8%Moderate 132 · 17.6%High 34 · 4.5%

OASIS moisturising mouthwash vs Experimental mouthwash formulation

Dry mouth (xerostomia) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…

1 finding from 1 review

Interventions for the management of dry mouth: topical therapies 2011 · Cochrane All outcomes
Shirodaria 2006 (crossover): OASIS reported to give a statistically significant improvement over subjects' normal remedies, but the report did not present the randomised OASIS-versus-experimental comparison; no data…
1 study
GRADE not reported

CMC/sorbitol pre-moistened swabs vs Lemon glycerin swabs

Patient preference · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…

1 finding from 1 review

Interventions for the management of dry mouth: topical therapies 2011 · Cochrane All outcomes
Patient preference favoured CMC/sorbitol (Chi2 10.89, df=1; P = 0.001).
1 study · 20 participants
GRADE not reported

Specific psychological therapy vs alternative specific psychological therapy

Clinical improvement: weight restoration to within the normal weight range for participant sample · people with severe and enduring anorexia nervosa

It is very uncertain whether specific psychological therapy changes clinical improvement: weight restoration to within the normal weight… compared with alternative specific psychological therapy (very low certainty).

1 finding from 1 review

Specific psychological therapies versus other therapies or no treatment for severe and enduring anorexia nervosa 2023 · Cochrane Headline outcomes only
RR 1.42 [0.66, 3.05]
1 study · 63 participants
Very low

Specific psychological therapy vs alternative specific psychological therapy

Treatment non‐completion: proportion of participants who did not complete treatment · people with severe and enduring anorexia nervosa

It is very uncertain whether specific psychological therapy changes treatment non‐completion: proportion of participants who did not… compared with alternative specific psychological therapy (very low certainty).

1 finding from 1 review

Specific psychological therapies versus other therapies or no treatment for severe and enduring anorexia nervosa 2023 · Cochrane Headline outcomes only
RR 1.72 [0.45, 6.59]
1 study · 63 participants
Very low

Specific psychological therapy vs alternative specific psychological therapy

Dropouts due to adverse events · people with severe and enduring anorexia nervosa

1 finding from 1 review

Specific psychological therapies versus other therapies or no treatment for severe and enduring anorexia nervosa 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
GRADE not reported

Intervention not reported

Total studies: 8 RCTs Total Participants: 9983 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 9983 participants
GRADE not reported

Intervention not reported

Severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 812(1 RCT)

The intervention showed no clear difference in severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants:… (low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.4 [0.45, 4.37]
1 study · 812 participants
Low

Intervention not reported

ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3063(3 RCTs)

The intervention showed no clear difference in ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.09 [0.99, 1.19]
3 studies · 6 participants
Low

Intervention not reported

ACQ responders at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1916(2 RCTs)

It is very uncertain whether the intervention changes ACQ responders at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (very low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.11 [0.91, 1.35]
2 studies · 6 participants
Very low

Intervention not reported

ACQ responders at 6 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 2480(2 RCTs)

The intervention showed no clear difference in ACQ responders at 6 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.02 [0.97, 1.08]
2 studies · 6 participants
Moderate

Intervention not reported

ACQ responders at 6 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 4818(4 RCTs)

The intervention probably leads to higher ACQ responders at 6 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.07 [1.01, 1.14]
4 studies · 6 participants
Moderate

Intervention not reported

ACQ responders at 6 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 2821(3 RCTs)

The intervention showed no clear difference in ACQ responders at 6 months ‐ HD TRIPLE vs MD TRIPLE№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.99 [0.95, 1.03]
3 studies · 6 participants
Moderate

Intervention not reported

ACQ responders at 6 months ‐ TRIPLE vs DUAL№ of participants: 7881(5 RCTs)

The intervention may leads to higher ACQ responders at 6 months ‐ TRIPLE vs DUAL№ of participants: 7881(5… (low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.09 [1.02, 1.15]
5 studies · 6 participants
Low

Intervention not reported

ACQ responders at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 2817(2 RCTs)

The intervention showed no clear difference in ACQ responders at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.99 [0.9, 1.07]
2 studies · 12 participants
Low

Intervention not reported

ACQ responders at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 2222(2 RCTs)

The intervention showed no clear difference in ACQ responders at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.01 [0.95, 1.07]
2 studies · 12 participants
Moderate

Intervention not reported

ACQ responders at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1088(1 RCT)

The intervention probably leads to higher ACQ responders at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.08 [1.01, 1.15]
1 study · 12 participants
Moderate

Intervention not reported

ACQ responders at 12 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 1631(1 RCT)

The intervention showed no clear difference in ACQ responders at 12 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.97 [0.91, 1.03]
1 study · 12 participants
Moderate

Intervention not reported

Severe exacerbations ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 1727(2 RCTs)

The intervention showed no clear difference in severe exacerbations ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants:… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.8 [0.45, 1.42]
2 studies · 1727 participants
Moderate

Intervention not reported

ACQ responders at 12 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 3982(3 RCTs)

It is very uncertain whether the intervention changes ACQ responders at 12 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of… (very low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.11 [0.99, 1.23]
3 studies · 12 participants
Very low

Intervention not reported

ACQ responders at 12 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 1089(1 RCT)

The intervention probably leads to higher ACQ responders at 12 months ‐ HD TRIPLE vs MD TRIPLE№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.08 [1.01, 1.16]
1 study · 12 participants
Moderate